Categories AlphaGraphs, Earnings, Energy

Schlumberger (SLB) reports $3.7 billion charges for Q2 2020

Schlumberger (NYSE: SLB) swung to a loss on a GAAP basis in the second quarter of 2020, hurt by the $3.7 billion of pretax restructuring and asset impairment charges. On an adjusted basis, the company reported a profit of 5 cents per share. Revenue declined 35% year-over-year to $5.36 billion.

SLB stock was down about 2% in the pre-marketing trading session.

Schlumberger (SLB) Q2 2020 Earnings Infograph

“The conditions are set in the third quarter for a modest frac completion activity increase in North America, though from a very low base. Internationally, markets may continue to be disrupted by the pandemic and will continue to adjust to budget levels set during the second quarter, but this would be mostly offset by the seasonal return of activity in the Northern Hemisphere and the rebound of Latin America from its second-quarter weakness,” said CEO Olivier Le Peuch.

Looking forward to listening to management/analysts comments on quarterly results? Stay tuned here for Schlumberger Q2 2020 earnings call transcript

Most Popular

Does Unity Software (U) stock has more room to run?

Last month, the IPO market was in a full swing. IPOs of Snowflake (NYSE: SNOW) and JFROG (NASDAQ: FROG) had an impressive opening day in September, the former creating a

PepsiCo (PEP): Steady snacking habits amid pandemic drive strong quarter for beverage giant

PepsiCo Inc. (NASDAQ: PEP) beat market expectations on both revenue and earnings for the third quarter of 2020. The company saw the momentum continue in its snacks business while the

Does the virus-driven boom make Electronic Arts (EA) a good investment?

With more and more people turning to virtual entertainment sources, amid the virus-related movement restrictions, video game publishers like Electronic Arts (NASDAQ: EA) are witnessing unusually high demand. Not surprisingly,

Leave a Reply

Your email address will not be published. Required fields are marked *

Add Comment
Loading...

Cancel
Viewing Highlight
Loading...
Highlight
Close
Top